RFI DRAFT - March 2025.docx

DEPARTMENT OF VETERANS AFFAIRS

Veterans Health Administration Consolidated Mail Outpatient Pharmacy (CMOP) 3450 S. 4th Street Leavenworth, KS 66048

The Department of Veterans Affairs is seeking interested sources for the requirement entitled:

CONSOLIDATED MAIL OUTPATIENT PHARMACY (CMOP) DOMESTIC PHARMACEUTICALS

This is a Sources Sought announcement only—this is not a Request for Proposal. The purpose of this notice is to conduct market research and obtain information from qualified contractors with special interest. No solicitation is being issued at this time. This notice shall not be construed as a commitment by the Government to ultimately award a contract, nor does it restrict the Government to a particular acquisition approach.

The Government has established an ongoing requirement for the provision of domestically manufactured pharmaceuticals. In accordance with Federal Acquisition Regulation (FAR) part 15.201(c), the Agency is encouraged to promote early exchanges of information about future acquisitions. An early exchange of information in the acquisition process can identify and resolve concerns regarding the acquisition strategy, including proposed contract type, terms and conditions, and acquisition planning schedules; the feasibility of the requirement, including performance requirements, statements of work, and data requirements; the suitability of the proposal instructions and evaluation criteria, including the approach for assessing past performance information; the availability of reference documents; and any other industry concerns or questions.

The Consolidated Mail Outpatient Pharmacy program (CMOP) is seeking potential small and large business domestic pharmaceutical manufacturer sources capable of providing the following pharmaceuticals:

1. Trazodone HCL - treatment of major depressive disorder (MDD) (common strength: 50MG; common bottle count: 100CT)

2. Sertraline HCL – treatment of major depressive disorder (MDD) (common strength: 100MG; common bottle count: 100CT)

3. Divalproex – treatment of seizure disorders, mental/mood conditions and to prevent migraines (common strength: 125MG; common bottle count: 100CT)

4. Zolpidem Tartrate – treatment for short-term insomnia (common strength: 5MG, 10MG, 12.5MG; common bottle count: 100CT, 500CT, 1000CT)

5. Hydroxychloroquine Sulfate – treatment of rheumatoid arthritis (common strength: 200MG; common bottle count: 100CT)

6. Errin – pregnancy contraceptive – (common strength: 0.35MG; common count: 28)

7. Camphor Menthol Methyl Salicylate Patches – for temporary relief of minor aches and pains of muscles and joints (common count: 60 patches)

Potential contractor(s) will manufacture the aforementioned pharmaceuticals domestically for an estimated seven facilities and will be responsible for providing all labor, materials, quality assurance, delivery and supervision in compliance with federal, state and local regulations. The North American Industry Classification System (NAICS) code associated with this request for information is: 325412, which has a business size standard of 1,250 employees. Interested manufacturers are reminded that in accordance with FAR 4.12, prospective contractors shall complete electronic annual representations and certifications in conjunction with FAR 4.11 required registration in the System for Award Management (SAM) database prior to award of a contract.

If you believe you are capable of meeting the requirement, please provide a complete capability statement and response by no later than April 3, 2025, at 16:30 CDT to Josie Linaweaver at josie.linaweaver@va.gov. A complete response satisfies the information requested below.

The Government requests responders provide the following information:

1) Company information including name, address, point of contact, identification of any socioeconomic categories (i.e. SDVOSB, VOSB, 8a, etc) the company falls under, business size and DUNS Number

2) The pharmaceutical(s) which are being manufactured domestically

3) Authorized distributors who distribute the domestically manufactured pharmaceutical(s)

4) Average cost of common prescription quantities

5) In the last twelve (12) months how many times has the stock not been available for shipment and how quickly are pharmaceuticals restocked

6) The contract number of any applicable GSA/FSS/NAC schedule if one exists from which these items can be procured under

PLEASE NOTE: This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.

image1.emf